Journal of Pathology and Translational Medicine

Reviews

Development of CytoAcademy: a new web- and mobile-based E-learning platform for cytopathologists and cytotechnologists by the Korean Society for Cytopathology in the post-pandemic era: Ran Hong, Yosep Chong, Seung Wan Chae, Seung-Sook Lee, Gyungyub Gong; J Pathol Transl Med. 2024;58(6):261-264. Published online November 7, 2024; DOI: https://doi.org/10.4132/jptm.2024.10.02

1,974 View
96 Download

Abstract PDF: Since the late 1990s, online e-learning has offered unparalleled convenience and affordability, becoming increasingly popular among pathologists. Traditional learning theories have been successfully applied to web/mobile-based learning systems, with mobile technologies even enhancing conventional offline education. In cytopathology, hands-on microscope training has traditionally been paramount, complemented by real-case presentations and lectures. However, the coronavirus disease 2019 (COVID-19) pandemic disrupted regular academic activities, making online e-learning platforms essential. We designed a web/mobile-based learning platform to enhance continued medical education in cytopathology at various levels, particularly during the era of COVID-19 and beyond. Since 2021, we have integrated curriculum materials, virtual education files, and whole-slide images (WSIs) of cytopathology, submitted from over 200 institutions across Korea, with the support of numerous instructors. We develop a new e-learning platform named “CytoAcademy” composed of a basic session for each organ and level across the range of morphologic findings; on-demand lectures to enhance cytopathologic knowledge; WSI archives that allow users to explore various histologically confirmed cases; and a self-assessment test to help organize diagnostic knowledge acquired through the web/mobile-friendly learning system. The platform provides not just an opportunity to achieve a correct diagnosis, but also a learning experience based on problem-solving point. Members interact, identify their deficiencies, and focus on specific educational materials. In this manner, all participants can actively engage in creating and maintaining knowledge and foster a proactive approach to learning.

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP: Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-Kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim; J Pathol Transl Med. 2024;58(4):147-164. Published online January 10, 2024; DOI: https://doi.org/10.4132/jptm.2023.11.01

3,088 View
446 Download

Abstract PDF: In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Case Study

A rare goblet cell adenocarcinoma arising from Barrett’s esophagus: the first reported case in the esophagus: Chi Eun Oh, Sung Eun Kim, Sun-Ju Oh; J Pathol Transl Med. 2024;58(2):81-86. Published online January 8, 2024; DOI: https://doi.org/10.4132/jptm.2023.12.26

1,825 View
287 Download

Abstract PDF: Goblet cell adenocarcinoma (GCA) is a rare and distinctive amphicrine tumor comprised of goblet-like mucinous cells and neuroendocrine cells. It is believed to originate from pluripotent stem cells located at the base of crypts. GCA predominantly arises from the appendix, with a few reported cases in extra-appendiceal locations such as the colorectum, small intestine, and stomach. In this case report, we present a unique instance of a 64-year-old male who initially received a diagnosis of neuroendocrine carcinoma in the distal esophagus based on biopsy but, following resection, was subsequently re-diagnosed with GCA arising from Barrett’s esophagus.

Original Articles

Postmortem lung and heart examination of COVID-19 patients in a case series from Jordan: Maram Abdaljaleel, Isra Tawalbeh, Malik Sallam, Amjad Bani Hani, Imad M. Al-Abdallat, Baheth Al Omari, Sahar Al-Mustafa, Hasan Abder-Rahman, Adnan Said Abbas, Mahmoud Zureigat, Mousa A. Al-Abbadi; J Pathol Transl Med. 2023;57(2):102-112. Published online March 14, 2023; DOI: https://doi.org/10.4132/jptm.2023.01.30

2,245 View
137 Download

Abstract PDF: Background
Coronavirus disease 2019 (COVID-19) has emerged as a pandemic for more than 2 years. Autopsy examination is an invaluable tool to understand the pathogenesis of emerging infections and their consequent mortalities. The aim of the current study was to present the lung and heart pathological findings of COVID-19–positive autopsies performed in Jordan.
Methods
The study involved medicolegal cases, where the cause of death was unclear and autopsy examination was mandated by law. We included the clinical and pathologic findings of routine gross and microscopic examination of cases that were positive for COVID-19 at time of death. Testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed through molecular detection by real-time polymerase chain reaction, serologic testing for IgM and electron microscope examination of lung samples.
Results
Seventeen autopsies were included, with male predominance (76.5%), Jordanians (70.6%), and 50 years as the mean age at time of death. Nine out of 16 cases (56.3%) had co-morbidities, with one case lacking such data. Histologic examination of lung tissue revealed diffuse alveolar damage in 13/17 cases (76.5%), and pulmonary microthrombi in 8/17 cases (47.1%). Microscopic cardiac findings were scarcely detected. Two patients died as a direct result of acute cardiac disease with limited pulmonary findings.
Conclusions
The detection of SARS-CoV-2 in postmortem examination can be an incidental or contributory finding which highlights the value of autopsy examination to determine the exact cause of death in controversial cases.

Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea: Sunhee Chang, Yoon-La Choi, Hyo Sup Shim, Geon Kook Lee, Seung Yeon Ha; J Pathol Transl Med. 2022;56(6):334-341. Published online October 27, 2022; DOI: https://doi.org/10.4132/jptm.2022.08.22

2,933 View
145 Download
9 Web of Science
4 Crossref

Abstract PDF

Background
Next-generation sequencing (NGS) is an approved test to select patients for BRAF V600E targeted therapy in Korea. However, the high cost, long turnaround times, and the need for sophisticated equipment and skilled personnel limit the use of NGS in daily practice. Immunohistochemistry (IHC) is a rapid and relatively inexpensive assay available in most laboratories. Therefore, in this study, we evaluate the usefulness of BRAF VE1 IHC in terms of predictive value and interobserver agreement in non–small cell lung cancers (NSCLCs).
Methods
A total of 30 cases with known BRAF mutation status were selected, including 20 cases of lung adenocarcinomas, six cases of colorectal adenocarcinomas, and four cases of papillary thyroid carcinomas. IHC for BRAF V600E was carried out using the VE1 antibody. Fifteen pathologists independently scored both the staining intensity and the percentage of tumor cell staining on whole slide images.
Results
In the lung adenocarcinoma subset, interobserver agreement for the percentage of tumor cell staining and staining intensity was good (percentage of tumor cell staining, intraclass correlation coefficient = 0.869; staining intensity, kappa = 0.849). The interobserver agreement for the interpretation using the cutoff of 40% was almost perfect in the entire study group and the lung adenocarcinoma subset (kappa = 0.815). Sensitivity, specificity, positive predictive value, and negative predictive value of BRAF VE1 IHC were 80.0%, 90.0%, 88.9%, and 81.8%, respectively.
Conclusions
BRAF VE1 IHC could be a screening test for the detection of BRAF V600E mutation in NSCLC. However, further studies are needed to optimize the protocol and to establish and validate interpretation criteria for BRAF VE1 IHC.

Citations

Citations to this article as recorded by

Dedifferentiated Leiomyosarcoma of the Uterine Corpus with Heterologous Component: Clinicopathological Analysis of Five Consecutive Cases from a Single Institution and Comprehensive Literature Review
Suyeon Kim, Hyunsik Bae, Hyun-Soo Kim
Diagnostics.2024; 14(2): 160. CrossRef
Differentiating BRAF V600E- and RAS-like alterations in encapsulated follicular patterned tumors through histologic features: a validation study
Chankyung Kim, Shipra Agarwal, Andrey Bychkov, Jen-Fan Hang, Agnes Stephanie Harahap, Mitsuyoshi Hirokawa, Kennichi Kakudo, Somboon Keelawat, Chih-Yi Liu, Zhiyan Liu, Truong Phan-Xuan Nguyen, Chanchal Rana, Huy Gia Vuong, Yun Zhu, Chan Kwon Jung
Virchows Archiv.2024; 484(4): 645. CrossRef
BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
Hyo Yeong Ahn, Chang Hun Lee, Min Ki Lee, Jung Seop Eom, Yeon Joo Jeong, Yeong Dae Kim, Jeong Su Cho, Jonggeun Lee, So Jeong Lee, Dong Hoon Shin, Ahrong Kim
Medicina.2023; 59(6): 1085. CrossRef
Reevaluating diagnostic categories and associated malignancy risks in thyroid core needle biopsy
Chan Kwon Jung
Journal of Pathology and Translational Medicine.2023; 57(4): 208. CrossRef

Reviews

Standardization of the pathologic diagnosis of appendiceal mucinous neoplasms: Dong-Wook Kang, Baek-hui Kim, Joon Mee Kim, Jihun Kim, Hee Jin Chang, Mee Soo Chang, Jin-Hee Sohn, Mee-Yon Cho, So-Young Jin, Hee Kyung Chang, Hye Seung Han, Jung Yeon Kim, Hee Sung Kim, Do Youn Park, Ha Young Park, So Jeong Lee, Wonae Lee, Hye Seung Lee, Yoo Na Kang, Younghee Choi; J Pathol Transl Med. 2021;55(4):247-264. Published online July 8, 2021; DOI: https://doi.org/10.4132/jptm.2021.05.28

10,901 View
834 Download
13 Web of Science
14 Crossref

Abstract PDF Supplementary Material

Although the understanding of appendiceal mucinous neoplasms (AMNs) and their relationship with disseminated peritoneal mucinous disease have advanced, the diagnosis, classification, and treatment of AMNs are still confusing for pathologists and clinicians. The Gastrointestinal Pathology Study Group of the Korean Society of Pathologists (GPSG-KSP) proposed a multicenter study and held a workshop for the “Standardization of the Pathologic Diagnosis of the Appendiceal Mucinous Neoplasm” to overcome the controversy and potential conflicts. The present article is focused on the diagnostic criteria, terminologies, tumor grading, pathologic staging, biologic behavior, treatment, and prognosis of AMNs and disseminated peritoneal mucinous disease. In addition, GPSG-KSP proposes a checklist of standard data elements of appendiceal epithelial neoplasms to standardize pathologic diagnosis. We hope the present article will provide pathologists with updated knowledge on how to handle and diagnose AMNs and disseminated peritoneal mucinous disease.

Citations

Citations to this article as recorded by

Lower Gastrointestinal Bleeding Secondary to Appendiceal Mucinous Neoplasm: A Report of Two Cases and a Review of the Literature
Jesús Omar Soto Llanes, Samanta Kin Dosal Limón, Ana Jimena Iberri Jaime, Mario Zambrano Lara, Billy Jiménez Bobadilla
Cureus.2024;[Epub] CrossRef
Predicting Survival in Mucinous Adenocarcinoma of the Appendix: Demographics, Disease Presentation, and Treatment Methodology
Paul H. McClelland, Stephanie N. Gregory, Shirley K. Nah, Jonathan M. Hernandez, Jeremy L. Davis, Andrew M. Blakely
Annals of Surgical Oncology.2024; 31(9): 6237. CrossRef
Histoséminaire biopsies péritonéales tumorales. Néoplasies mucineuses appendiculaires
Peggy Dartigues
Annales de Pathologie.2024; 44(4): 274. CrossRef
Histoséminaire biopsies péritonéales tumorales. Cas no 2
Peggy Dartigues
Annales de Pathologie.2024; 44(4): 245. CrossRef
A Case of Low-Grade Appendiceal Mucinous Neoplasm: The Role of Preoperative Imaging and Surgical Technique in Achieving Favorable Outcomes
Daniel A Meza-Martinez, Yeudiel Suro Santos, Samantha J Andrade-Ordoñez, Julio A Palomino-Payan, Brando J Fematt-Rodriguez
Cureus.2024;[Epub] CrossRef
Incidental Appendiceal Mucinous Neoplasm Found During Appendectomy in a 15-Year-Old Patient: A Case Report
Fernando Aguilar-Ruiz, Kevin Joseph Fuentes-Calvo, Sara Fernanda Arechavala-Lopez, Irving Fuentes-Calvo, Luis F Arias-Ruiz
Cureus.2024;[Epub] CrossRef
Uncovering the Hidden Threat: Ileocolic Intussusception in an Adult With Appendicular Tumor
Mrunal Panchal, Shishir Kumar, Khushboo Jha, Kaushik Saha, Abhijit Kundu
Cureus.2024;[Epub] CrossRef
Low-Grade Appendiceal Mucinous Neoplasm vs. Appendiceal Diverticulum: Distinction with Histomorphologic Features
Cevriye Cansiz Ersöz, Siyar Ersöz, Berna Savas, Arzu Ensari
Gastrointestinal Disorders.2024; 6(4): 905. CrossRef
Appendiceal perforation secondary to endometriosis with intestinal metaplasia: A case report
Minghua Wang, Jing Liu, Boxin Hu, Simin Wang, Ping Xie, Ping Li
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef
Primary and secondary tumors of the peritoneum: key imaging features and differential diagnosis with surgical and pathological correlation
Javier Miguez González, Francesc Calaf Forn, Laura Pelegrí Martínez, Pilar Lozano Arranz, Rafael Oliveira Caiafa, Jordi Català Forteza, Lina Maria Palacio Arteaga, Ferrán Losa Gaspà, Isabel Ramos Bernadó, Pedro Barrios Sánchez, Juan Ramón Ayuso Colella
Insights into Imaging.2023;[Epub] CrossRef
Muzinöse Tumoren des Peritoneums
Anne Kristin Fischer, Andrea Tannapfel, Alexander Quaas
Die Chirurgie.2023; 94(10): 823. CrossRef
Landscape of Genetic Mutations in Appendiceal Cancers
Marian Constantin, Cristina Mătanie, Livia Petrescu, Alexandra Bolocan, Octavian Andronic, Coralia Bleotu, Mihaela Magdalena Mitache, Sorin Tudorache, Corneliu Ovidiu Vrancianu
Cancers.2023; 15(14): 3591. CrossRef
Delivery of an Incidental Appendiceal Mucinous Neoplasm
Madison Bowles, Jessica Y Ng, Hajir Nabi
Cureus.2022;[Epub] CrossRef
Unearthing novel fusions as therapeutic targets in solid tumors using targeted RNA sequencing
Sungbin An, Hyun Hee Koh, Eun Sol Chang, Juyoung Choi, Ji-Young Song, Mi-Sook Lee, Yoon-La Choi
Frontiers in Oncology.2022;[Epub] CrossRef

Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group: Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee; J Pathol Transl Med. 2021;55(3):181-191. Published online May 11, 2021; DOI: https://doi.org/10.4132/jptm.2021.03.23

6,388 View
317 Download
14 Web of Science
14 Crossref

Abstract PDF

Molecular biomarker testing is the standard of care for non–small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.

Citations

Citations to this article as recorded by

Clinical utility of the Oncomine Dx Target Testmulti‐CDxsystem and the possibility of utilizing those original sequence data
Ayaka Saito, Hideki Terai, Tae‐Jung Kim, Katsura Emoto, Ryutaro Kawano, Kohei Nakamura, Hideyuki Hayashi, Hatsuyo Takaoka, Akihiko Ogata, Katsuhito Kinoshita, Fumimaro Ito, Lisa Shigematsu, Masahiko Okada, Takahiro Fukushima, Akifumi Mitsuishi, Taro Shino
Cancer Medicine.2024;[Epub] CrossRef
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
Yurimi Lee, Boram Lee, Yoon-La Choi, Dong-Wook Kang, Joungho Han
Modern Pathology.2024; 37(6): 100490. CrossRef
Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer
Shilpi Thakur, Amber Rathor, Surabhi Jain, Aruna Nambirajan, Sachin Khurana, Prabhat Singh Malik, Deepali Jain
Journal of the American Society of Cytopathology.2024; 13(4): 291. CrossRef
A Novel Dual-labeled Peptide for Multimodal Imaging of EGFR with L858R Mutation
Myoung Hyoun Kim, Seul-Gi Kim, Dae-Weung Kim
Current Radiopharmaceuticals.2024; 17(2): 174. CrossRef
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer
Adam Szpechcinski, Joanna Moes-Sosnowska, Paulina Skronska, Urszula Lechowicz, Magdalena Pelc, Malgorzata Szolkowska, Piotr Rudzinski, Emil Wojda, Krystyna Maszkowska-Kopij, Renata Langfort, Tadeusz Orlowski, Pawel Sliwinski, Mateusz Polaczek, Joanna Chor
International Journal of Molecular Sciences.2024; 25(14): 7908. CrossRef
Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer
Dong-Won Kang, Sun-Kyeong Park, Sokbom Kang, Eui-Kyung Lee
Lung Cancer.2024; 197: 107970. CrossRef
FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC
Anke Behnke, Anne Cayre, Giovanna De Maglio, Giuseppe Giannini, Lionel Habran, Marina Tarsitano, Massimiliano Chetta, David Cappellen, Alexandra Lespagnol, Cecile Le Naoures, Gabriella Massazza, Annarita Destro, Irina Bonzheim, Achim Rau, Achim Battmann,
Pathology and Oncology Research.2023;[Epub] CrossRef
Problems in the Pathologic Diagnosis of Suspected Lung Cancer
Soo Han Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom
Tuberculosis and Respiratory Diseases.2023; 86(3): 176. CrossRef
Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics
Hyun Hee Koh, Eunhyang Park, Hyun-Soo Kim
Diagnostics.2022; 12(2): 326. CrossRef
Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics
Yurimi Lee, Kiyong Na, Ha Young Woo, Hyun-Soo Kim
Diagnostics.2022; 12(5): 1102. CrossRef
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef
Biomarker testing of cytology specimens in personalized medicine for lung cancer patients
Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(6): 326. CrossRef
Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea
Sunhee Chang, Yoon-La Choi, Hyo Sup Shim, Geon Kook Lee, Seung Yeon Ha
Journal of Pathology and Translational Medicine.2022; 56(6): 334. CrossRef
Lung Cancer in Korea
Sehhoon Park, Chang-Min Choi, Seung-Sik Hwang, Yoon-La Choi, Hyae Young Kim, Young-Chul Kim, Young Tae Kim, Ho Yun Lee, Si Yeol Song, Myung-Ju Ahn
Journal of Thoracic Oncology.2021; 16(12): 1988. CrossRef

PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future: Hyojin Kim, Jin-Haeng Chung; J Pathol Transl Med. 2019;53(4):199-206. Published online May 2, 2019; DOI: https://doi.org/10.4132/jptm.2019.04.24; Correction in: J Pathol Transl Med 2020;54(2):196

14,784 View
637 Download
62 Web of Science
57 Crossref

Abstract PDF

Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is the only available biomarker that can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer. Because each PD-1/PD-L1 blockade was approved together with a specific PD-L1 IHC assay used in the clinical trials, pathologists have been challenged with performing various assays with a limited sample. To provide a more unified understanding of this, several cross-validation studies between platforms have been performed and showed consistent results. However, the interchangeability of assays may be limited in practice because of the risk of misclassification of patients for the treatment. Furthermore, several issues, including the temporal and spatial heterogeneity of PD-L1 expression in the tumor, and the potential for cytology specimens to be used as an alternative to tissue samples for PD-L1 testing, have still not been resolved. In the future, one of the main aims of immunotherapy research should be to find a novel predictive biomarker for PD-1 blockade therapy and a way to combine it with PD-L1 IHC and other tests.

Citations

Citations to this article as recorded by

Precision Oncology in Lung Cancer Surgery
Patrick Bou-Samra, Sunil Singhal
Surgical Oncology Clinics of North America.2024; 33(2): 311. CrossRef
Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience
Kashif Asghar, Shaarif Bashir, Muhammad Hassan, Asim Farooq, Muhammad Abu Bakar, Sundus Bilal, Maryam Hameed, Shafqat Mehmood, Asif Loya
Egyptian Liver Journal.2024;[Epub] CrossRef
Engineering Proteus mirabilis improves antitumor efficacy via enhancing cytotoxic T cell responses
Hong Zhang, Yinlin Luo, Xincheng Zhao, Xiande Liu
Molecular Therapy: Oncology.2024; 32(1): 200770. CrossRef
Unlocking the potential of oncology biomarkers: advancements in clinical theranostics
Ankit Kumar Dubey, Ishnoor Kaur, Reecha Madaan, Shikha Raheja, Rajni Bala, Manoj Garg, Suresh Kumar, Viney Lather, Vineet Mittal, Deepti Pandita, Rohit Gundamaraju, Rajeev K. Singla, Rohit Sharma
Drug Metabolism and Personalized Therapy.2024; 39(1): 5. CrossRef
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
Uiju Cho, Soyoung Im, Hyung Soon Park
Journal of Pathology and Translational Medicine.2024; 58(2): 49. CrossRef
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling
Miriam Schirru, Hamza Charef, Khalil-Elmehdi Ismaili, Frédérique Fenneteau, Didier Zugaj, Pierre-Olivier Tremblay, Fahima Nekka
Journal of Pharmacokinetics and Pharmacodynamics.2024; 51(4): 319. CrossRef
Predictions of PD-L1 Expression Based on CT Imaging Features in Lung Squamous Cell Carcinoma
Seong Hee Yeo, Hyun Jung Yoon, Injoong Kim, Yeo Jin Kim, Young Lee, Yoon Ki Cha, So Hyeon Bak
Journal of the Korean Society of Radiology.2024; 85(2): 394. CrossRef
Assessment of Programmed Cell Death Ligand-1 Expression in Non-small Cell Lung Carcinomas by Immunohistochemistry
Sandeep Mani, Archana Lakshmanan, Annapurneswari Subramanyan
Apollo Medicine.2024; 21(1): 57. CrossRef
The efficacy of immune checkpoint inhibitors on low PD‐L1 cervical cancer: A meta‐analysis
Wutao Chen, Nan Zhang, Zhihong He, Qing Li, You Wang, Weihua Lou, Wen Di
Health Science Reports.2024;[Epub] CrossRef
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer
Arpeet T. Shah, Isabelle Blanchard, Sukhmani K. Padda, Heather A. Wakelee, Joel W. Neal
Clinical Lung Cancer.2024; 25(6): 550. CrossRef
Optimizing immunofluorescence with high-dynamic-range imaging to enhance PD-L1 expression evaluation for 3D pathology assessment from NSCLC tumor tissue
Hsien-Neng Huang, Chun-Wei Kuo, Yu-Ling Hung, Chia-Hung Yang, Yu-Han Hsieh, Yu-Chieh Lin, Margaret Dah-Tsyr Chang, Yen-Yin Lin, Jen-Chung Ko
Scientific Reports.2024;[Epub] CrossRef
The Role of Programmed Cell Death Ligand 1 Expression in Pituitary Tumours: Lessons from the Current Literature
Mariana Lopes-Pinto, Ema Lacerda-Nobre, Ana Luísa Silva, Francisco Tortosa, Pedro Marques
Neuroendocrinology.2024; 114(8): 709. CrossRef
Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy
Zihan Xu, Huien Zhang, Guikai Ma, Wenjuan Meng, Junliang Du, Xin Wu, Baohong Yang, Ningning Wang, Yanhong Ding, Qingyun Zhang, Na Li, Xuede Zhang, Guohua Yu, Shuzhen Liu, Zhenhua Li
Oncology Letters.2024;[Epub] CrossRef
Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor
Hitomi Nakatsukasa, Masaya Takahashi, Masahito Shibano, Yusuke Ishigami, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda
International Journal of Clinical Oncology.2024;[Epub] CrossRef
Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer
Guanghui Gao, Longgang Cui, Fei Zhou, Tao Jiang, Wanying Wang, Shiqi Mao, Fengying Wu, Fangli Jiang, Bei Zhang, Ting Bei, Wenchuan Xie, Cheng Zhang, Hougang Zhang, Chan Gao, Xiaochen Zhao, Yuezong Bai, Caicun Zhou, Shengxiang Ren
International Journal of Cancer.2023; 152(1): 79. CrossRef
Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma
Jiwon Koh, Haeryoung Kim, Kyung Chul Moon, Cheol Lee, Kyoungbun Lee, Han Suk Ryu, Kyeong Cheon Jung, Yoon Kyung Jeon
American Journal of Surgical Pathology.2023; 47(2): 183. CrossRef
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer
Moonsik Kim, Ji Yun Jeong, An Na Seo
Diagnostics.2023; 13(17): 2782. CrossRef
PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
Giulia Cossu, Stefano La Rosa, Jean Philippe Brouland, Nelly Pitteloud, Ethan Harel, Federico Santoni, Maxime Brunner, Roy Thomas Daniel, Mahmoud Messerer
Cancers.2023; 15(18): 4471. CrossRef
Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis
Jeongwan Kang, Kang Min Han, Hera Jung, Hyunchul Kim
Diagnostics.2023; 13(20): 3258. CrossRef
A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?
Anita Tranberg Simonsen, Amalie Utke, Johanne Lade-Keller, Lasse Westphal Thomsen, Torben Steiniche, Magnus Stougaard
Experimental and Molecular Pathology.2022; 125: 104749. CrossRef
Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review
Swati Satturwar, Ilaria Girolami, Enrico Munari, Francesco Ciompi, Albino Eccher, Liron Pantanowitz
Diagnostic Cytopathology.2022; 50(6): 313. CrossRef
Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
Yen-Yu Lin, Lei-Chi Wang, Yu-Han Hsieh, Yu-Ling Hung, Yung-An Chen, Yu-Chieh Lin, Yen-Yin Lin, Teh-Ying Chou
Journal of Translational Medicine.2022;[Epub] CrossRef
Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
Cristina-Florina Pirlog, Horia Teodor Cotan, Andreea Parosanu, Cristina Orlov Slavu, Ana Maria Popa, Cristian Iaciu, Mihaela Olaru, Alexandru Vlad Oprita, Irina Nita, Cornelia Nitipir
Cureus.2022;[Epub] CrossRef
Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
Frédérique Penault-Llorca, Keith M. Kerr, Pilar Garrido, Erik Thunnissen, Elisabeth Dequeker, Nicola Normanno, Simon J. Patton, Jenni Fairley, Joshua Kapp, Daniëlle de Ridder, Aleš Ryška, Holger Moch
Virchows Archiv.2022; 481(3): 351. CrossRef
Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Chih-Cheng Tsao, Hsin-Hung Wu, Ying-Fu Wang, Po-Chien Shen, Wen-Ting Wu, Huang-Yun Chen, Yang-Hong Dai
Biomedicines.2022; 10(7): 1539. CrossRef
Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites
Wenqi Ti, Tianhui Wei, Jianbo Wang, Yufeng Cheng
Frontiers in Immunology.2022;[Epub] CrossRef
Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer
Kai Hong, Yingjue Zhang, Lingli Yao, Jiabo Zhang, Xianneng Sheng, Lihua Song, Yu Guo, Yangyang Guo
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Molecular imaging of immune checkpoints in oncology: Current and future applications
Shushan Ge, Tongtong Jia, Jihui Li, Bin Zhang, Shengming Deng, Shibiao Sang
Cancer Letters.2022; 548: 215896. CrossRef
PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
Katerina Hadrava Vanova, Ondrej Uher, Leah Meuter, Suman Ghosal, Sara Talvacchio, Mayank Patel, Jiri Neuzil, Karel Pacak
Frontiers in Oncology.2022;[Epub] CrossRef
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
Nicoletta Provinciali, Marco Greppi, Silvia Pesce, Mariangela Rutigliani, Irene Maria Briata, Tania Buttiron Webber, Marianna Fava, Andrea DeCensi, Emanuela Marcenaro
Frontiers in Immunology.2022;[Epub] CrossRef
PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
John Turchini, Loretta Sioson, Adele Clarkson, Amy Sheen, Anthony J. Gill
Endocrine Pathology.2021; 32(3): 408. CrossRef
Comprehensive tumor molecular profile analysis in clinical practice
Mustafa Özdoğan, Eirini Papadopoulou, Nikolaos Tsoulos, Aikaterini Tsantikidi, Vasiliki-Metaxa Mariatou, Georgios Tsaousis, Evgenia Kapeni, Evgenia Bourkoula, Dimitrios Fotiou, Georgios Kapetsis, Ioannis Boukovinas, Nikolaos Touroutoglou, Athanasios Fassa
BMC Medical Genomics.2021;[Epub] CrossRef
CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study
Zekun Jiang, Yinjun Dong, Linke Yang, Yunhong Lv, Shuai Dong, Shuanghu Yuan, Dengwang Li, Liheng Liu
Journal of Digital Imaging.2021; 34(5): 1073. CrossRef
Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics
Pierre Murchan, Cathal Ó’Brien, Shane O’Connell, Ciara S. McNevin, Anne-Marie Baird, Orla Sheils, Pilib Ó Broin, Stephen P. Finn
Diagnostics.2021; 11(8): 1406. CrossRef
Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic
David Leung, Samuel Bonacorsi, Ralph Adam Smith, Wolfgang Weber, Wendy Hayes
Frontiers in Oncology.2021;[Epub] CrossRef
A Comparative Study of Immunotherapy as Second-Line Treatment and beyond in Patients with Advanced Non-Small-Cell Lung Carcinoma
Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Ma
Lung Cancer Management.2021;[Epub] CrossRef
Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab
Taisuke Araki, Kazunari Tateishi, Kei Sonehara, Shuko Hirota, Masamichi Komatsu, Manabu Yamamoto, Shintaro Kanda, Hiroshi Kuraishi, Masayuki Hanaoka, Tomonobu Koizumi
Thoracic Cancer.2021; 12(5): 603. CrossRef
Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis
Qiong-ying Hu, Yun Yuan, Yu-chen Li, Lu-yao Yang, Xiang-yu Zhou, Da-qian Xiong, Zi-yi Zhao, Hiroshi Tanaka
BioMed Research International.2021; 2021: 1. CrossRef
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study
Belen Rubio-Viqueira, Margarita Majem Tarruella, Martín Lázaro, Sergio Vázquez Estévez, Juan Felipe Córdoba-Ortega, Inmaculada Maestu Maiques, Jorge García González, Ana Blasco Cordellat, Javier Valdivia-Bautista, Carmen González Arenas, Jose Miguel Sánch
Lung Cancer Management.2021;[Epub] CrossRef
Can Systems Biology Advance Clinical Precision Oncology?
Andrea Rocca, Boris N. Kholodenko
Cancers.2021; 13(24): 6312. CrossRef
Do we need PD‐L1 as a biomarker for thyroid cytologic and histologic specimens?
Marc P. Pusztaszeri, Massimo Bongiovanni, Fadi Brimo
Cancer Cytopathology.2020; 128(3): 160. CrossRef
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Andrea Botticelli, Pamela Vernocchi, Federico Marini, Andrea Quagliariello, Bruna Cerbelli, Sofia Reddel, Federica Del Chierico, Francesca Di Pietro, Raffaele Giusti, Alberta Tomassini, Ottavia Giampaoli, Alfredo Miccheli, Ilaria Grazia Zizzari, Marianna
Journal of Translational Medicine.2020;[Epub] CrossRef
Immune checkpoint inhibitors in advanced non–small cell lung cancer: A metacentric experience from India
Santosh Kumar, Srujana Joga, Bivas Biswas, Deepak Dabkara, Kuruswamy Thurai Prasad, Navneet Singh, Prabhat Singh Malik, Sachin Khurana, Sandip Ganguly, Valliappan Muthu, Ullas Batra
Current Problems in Cancer.2020; 44(3): 100549. CrossRef
Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
Jiyoung Yoon, Young Joo Suh, Kyunghwa Han, Hyoun Cho, Hye‐Jeong Lee, Jin Hur, Byoung Wook Choi
Thoracic Cancer.2020; 11(4): 993. CrossRef
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm
Lars H. Breimer, Petros Nousios, Louise Olsson, Hans Brunnström
Scandinavian Journal of Clinical and Laboratory Investigation.2020; 80(5): 360. CrossRef
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, Francois Ghiringhelli
European Journal of Cancer.2020; 131: 40. CrossRef
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
Cancers.2020; 12(5): 1125. CrossRef
Current status and future perspectives of liquid biopsy in non-small cell lung cancer
Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim
Journal of Pathology and Translational Medicine.2020; 54(3): 204. CrossRef
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
Fabio Pagni, Umberto Malapelle, Claudio Doglioni, Gabriella Fontanini, Filippo Fraggetta, Paolo Graziano, Antonio Marchetti, Elena Guerini Rocco, Pasquale Pisapia, Elena V. Vigliar, Fiamma Buttitta, Marta Jaconi, Nicola Fusco, Massimo Barberis, Giancarlo
Cancers.2020; 12(7): 1800. CrossRef
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
Ana Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, Hugo Arasanz, Luisa Chocarro, Miren Zuazo, Pilar Morente, Ruth Vera, David Escors, Grazyna Kochan
International Journal of Molecular Sciences.2020; 21(16): 5918. CrossRef
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, Irene Braña, June Y. Hou, Daniel Cho, Gerald S. Falchook, Silvia Formenti, Salma Jabbour, Kathleen Moore, Aung Naing, Kyriakos P. Papadopoulos, Joaquina Baranda, Wen Fury, Minjie Feng, Elizabeth St
Gynecologic Oncology.2020; 159(2): 322. CrossRef
Atezolizumab: A Review in Extensive-Stage SCLC
James E. Frampton
Drugs.2020; 80(15): 1587. CrossRef
Prognostic and clinicopathological roles of programmed death‐ligand 1 (PD‐L1) expression in thymic epithelial tumors: A meta‐analysis
Hyun Min Koh, Bo Gun Jang, Hyun Ju Lee, Chang Lim Hyun
Thoracic Cancer.2020; 11(11): 3086. CrossRef
Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten
Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vollome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
Kompass Pneumologie.2020; 8(6): 300. CrossRef
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Seung Eun Lee, Yu Jin Kim, Minjung Sung, Mi-Sook Lee, Joungho Han, Hong Kwan Kim, Yoon-La Choi
International Journal of Molecular Sciences.2019; 20(19): 4794. CrossRef
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers
João Lobo, Ângelo Rodrigues, Rita Guimarães, Mariana Cantante, Paula Lopes, Joaquina Maurício, Jorge Oliveira, Carmen Jerónimo, Rui Henrique
Cancers.2019; 11(10): 1535. CrossRef
Basis of PD1/PD-L1 Therapies
Barbara Seliger
Journal of Clinical Medicine.2019; 8(12): 2168. CrossRef

Molecular Testing of Lung Cancers: Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee; J Pathol Transl Med. 2017;51(3):242-254. Published online April 21, 2017; DOI: https://doi.org/10.4132/jptm.2017.04.10

14,545 View
598 Download
26 Web of Science
26 Crossref

Abstract PDF

Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.

Citations

Citations to this article as recorded by

Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes
Raquel Ramos, Conceição Souto Moura, Mariana Costa, Nuno Jorge Lamas, Renato Correia, Diogo Garcez, José Miguel Pereira, Carlos Sousa, Nuno Vale
Journal of Personalized Medicine.2024; 14(5): 446. CrossRef
Evolution of therapy for ALK-positive lung carcinomas: Application of third-generation ALK inhibitors in real clinical practice
A. F. Nasretdinov, A. V. Sultanbaev, Sh. I. Musin, K. V. Menshikov, R. T. Ayupov, A. A. Izmailov, G. A. Serebrennikov, V. E. Askarov, D. V. Feoktistov
Meditsinskiy sovet = Medical Council.2024; (10): 74. CrossRef
Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer
Dong-Won Kang, Sun-Kyeong Park, Sokbom Kang, Eui-Kyung Lee
Lung Cancer.2024; 197: 107970. CrossRef
miR-92a-3p regulates cisplatin-induced cancer cell death
Romain Larrue, Sandy Fellah, Nihad Boukrout, Corentin De Sousa, Julie Lemaire, Carolane Leboeuf, Marine Goujon, Michael Perrais, Bernard Mari, Christelle Cauffiez, Nicolas Pottier, Cynthia Van der Hauwaert
Cell Death & Disease.2023;[Epub] CrossRef
Diagnostic Approach of Lung Cancer: A Literature Review
Jesi Hana, Novia Nurul Faizah
Jurnal Respirasi.2023; 9(2): 141. CrossRef
Molecular Pathology of Lung Cancer
James J. Saller, Theresa A. Boyle
Cold Spring Harbor Perspectives in Medicine.2022; 12(3): a037812. CrossRef
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee, Kyoung Song, Hannah Lee, Ryong Nam Kim, Young Kee Shin, Doo-Yi Oh, Yoon-La Choi
Cancer Research and Treatment.2021; 53(1): 9. CrossRef
The promises and challenges of early non‐small cell lung cancer detection: patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers
Lukas Kalinke, Ricky Thakrar, Sam M. Janes
Molecular Oncology.2021; 15(10): 2544. CrossRef
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park, Chanhyun Park
Expert Review of Pharmacoeconomics & Outcomes Research.2021; 21(3): 381. CrossRef
The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
Parth Shah, Jacob Sands, Nicola Normanno
Lung Cancer.2021; 160: 118. CrossRef
Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
OncoTargets and Therapy.2021; Volume 14: 4671. CrossRef
Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
Melina E. Marmarelis, Corey J. Langer
Clinical Lung Cancer.2020; 21(5): 395. CrossRef
Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
Eunhyang Park, Hyo Sup Shim
Cancer Research and Treatment.2020; 52(2): 543. CrossRef
High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
Yuyin Xu, Heng Chang, Lijing Wu, Xin Zhang, Ling Zhang, Jing Zhang, Yuan Li, Lei Shen, Xiaoli Zhu, Xiaoyan Zhou, Qianming Bai
Experimental and Molecular Pathology.2020; 117: 104548. CrossRef
An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
Jiacong Wei, Anna A. Rybczynska, Pei Meng, Martijn Terpstra, Ali Saber, Jantine Sietzema, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry. J.M. Groen, Anthonie van der Wekken, Anke van den Berg, Klaas Kok
Cancers.2020; 12(10): 2843. CrossRef
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
Alexander Gavralidis, Justin F. Gainor
The Cancer Journal.2020; 26(6): 517. CrossRef
Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors
Jasna Metovic, Luisella Righi, Luisa Delsedime, Marco Volante, Mauro Papotti
Acta Cytologica.2020; 64(1-2): 16. CrossRef
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer
Eun Kyung Kim, Kyung A. Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim
Clinical Lung Cancer.2019; 20(1): e123. CrossRef
PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
Jongmin Lee, Chan Kwon Park, Hyoung‐Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae‐Jung Kim
Thoracic Cancer.2019; 10(1): 103. CrossRef
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
Yeon Bi Han, Hyun Jung Kwon, Soo Young Park, Eun-Sun Kim, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2019; 53(2): 86. CrossRef
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
Lung Cancer.2019; 136: 65. CrossRef
Somatic mutations and immune checkpoint biomarkers
Brielle A. Parris, Eloise Shaw, Brendan Pang, Richie Soong, Kwun Fong, Ross A. Soo
Respirology.2019; 24(3): 215. CrossRef
Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
Anna Chalmers, Laura Cannon, Wallace Akerley
The Oncologist.2019; 24(7): 963. CrossRef
Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces
Jae Seok Lee, Eun Kyung Kim, Moonsik Kim, Hyo Sup Shim
Lung Cancer.2018; 123: 121. CrossRef

Original Articles

Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria: Soohyun Hwang, Joungho Han, Misun Choi, Myung-Ju Ahn, Yong Soo Choi; J Pathol Transl Med. 2017;51(1):56-68. Published online October 16, 2016; DOI: https://doi.org/10.4132/jptm.2016.09.17

9,545 View
229 Download
8 Web of Science
7 Crossref

Abstract PDF

Background
We reviewed a series of 188 resected pulmonary mucinous adenocarcinomas (MAs) to clarify the prognostic significance of lepidic and non-lepidic patterns.
Methods
Non-lepidic patterns were divided into bland, non-distorted acini with uncertain invasiveness (pattern 1), unequivocal invasion into stroma (pattern 2), or invasion into alveolar spaces (pattern 3).
Results
The mean proportion of invasive patterns (patterns 2 and 3) was lowest in small (≤ 3 cm) tumors, and gradually increased in intermediate (> 3 cm and ≤ 7 cm) and large (> 7 cm) tumors (8.4%, 34.3%, and 50.1%, respectively). Adjusted T (aT) stage, as determined by the size of invasive patterns, was positively correlated with adverse histologic and clinical features including older age, male sex, and ever smokers. aTis tumors, which were exclusively composed of lepidic pattern (n = 9), or a mixture of lepidic and pattern 1 (n = 40) without any invasive patterns, showed 100% disease- free survival (DFS). The aT1mi tumors, with minimal (≤ 5 mm) invasive patterns (n = 63), showed a 95.2% 5-year DFS, with recurrences (n = 2) limited to tumors greater than 3 cm in total size (n = 23). Both T and aT stage were significantly associated with DFS; however, survival within the separate T-stage subgroups was stratified according to the aT stage, most notably in the intermediatestage subgroups. In multivariate analysis, the size of invasive patterns (p = .020), pleural invasion (p < .001), and vascular invasion (p = .048) were independent predictors of recurrence, whereas total size failed to achieve statistical significance (p = .121).
Conclusions
This study provides a rationale for histologic risk stratification in pulmonary MA based on the extent of invasive growth patterns with refined criteria for invasion.

Citations

Citations to this article as recorded by

Distinct Recurrence Pattern and Survival Outcomes of Invasive Mucinous Adenocarcinoma of the Lung: The Potential Role of Local Therapy in Intrapulmonary Spread
Dong Woog Yoon, Soohyun Hwang, Tae Hee Hong, Yoon-La Choi, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Young Mog Shim, Jong Ho Cho
Annals of Surgical Oncology.2024; 31(1): 201. CrossRef
Pulmonary invasive mucinous adenocarcinoma
Wei‐Chin Chang, Yu Zhi Zhang, Andrew G Nicholson
Histopathology.2024; 84(1): 18. CrossRef
Micropapillary Pattern in Invasive Mucinous Adenocarcinoma of the Lung: Comparison With Invasive Non-Mucinous Adenocarcinoma
Hui He, Lue Li, Yuan-yuan Wen, Li-yong Qian, Zhi-qiang Yang
International Journal of Surgical Pathology.2024; 32(5): 926. CrossRef
Radiological and clinical features of screening-detected pulmonary invasive mucinous adenocarcinoma
Dae Hyeon Kim, So Young Bae, Kwon Joong Na, Samina Park, In Kyu Park, Chang Hyun Kang, Young Tae Kim
Interactive CardioVascular and Thoracic Surgery.2022; 34(2): 229. CrossRef
Micropapillary Pattern in Invasive Mucinous Adenocarcinoma of the Lung: Comparison with Invasive Non-Mucinous Adenocarcinoma
Hui He, Yuanyuan Wen, Liyong Qian, Zhiqiang Yang
SSRN Electronic Journal .2022;[Epub] CrossRef
Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung
Tomonari Oki, Keiju Aokage, Shogo Nomura, Kenta Tane, Tomohiro Miyoshi, Norihiko Shiiya, Kazuhito Funai, Masahiro Tsuboi, Genichiro Ishii
Journal of Cancer Research and Clinical Oncology.2020; 146(5): 1291. CrossRef
Prognostic Impact of Histopathologic Features in Pulmonary Invasive Mucinous Adenocarcinomas
Wei-Chin Chang, Yu Zhi Zhang, Eric Lim, Andrew G Nicholson
American Journal of Clinical Pathology.2020; 154(1): 88. CrossRef

Review of Medical Advisory Services by the Korean Society of Pathologists from 2003 to 2014: Min Hye Jang, Geon Kook Lee, Han Seong Kim, Wan Seop Kim; J Pathol Transl Med. 2016;50(1):37-44. Published online November 17, 2015; DOI: https://doi.org/10.4132/jptm.2015.09.18

7,535 View
57 Download
1 Web of Science

Abstract PDF Supplementary Material: Background
Since 2003, the Korean Society of Pathologists (KSP) has been officially providing medical advisory services (MAS). We reviewed the cases submitted to the KSP between 2003 and 2014. Methods: In total, 1,950 cases were submitted, most by private health insurance companies. The main purposes of the consultations were to clarify the initial diagnoses and to assign a proper disease classification code. We comprehensively reviewed 1,803 consultation cases with detailed information. Results: In spite of some fluctuations, the number of submitted cases has been significantly increasing over the 12 study years. The colon and rectum (40.3%), urinary bladder (14.2%), and stomach (6.9%) were the three most common tissues of origin. The most common diagnoses for each of the three tissues of origin were neuroendocrine tumor (50.7%), non-invasive papillary urothelial carcinoma (70.7%), and adenocarcinoma (36.2%). Regardless of the tissue of origin, neuroendocrine tumor of the digestive system was the most common diagnosis (419 of 1,803). Conclusions: In the current study, we found that pathologic consultations associated with private health insurance accounted for a large proportion of the MAS. Coding of the biologic behavior of diseases was the main issue of the consultations. In spite of the effort of the KSP to set proper guidelines for coding and classification of tumors, this review revealed that problems still exist and will continue to be an important issue.

Reviews

Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives: Yoon Young Choi, Sung Hoon Noh, Jae-Ho Cheong; J Pathol Transl Med. 2016;50(1):1-9. Published online October 26, 2015; DOI: https://doi.org/10.4132/jptm.2015.09.10

12,463 View
153 Download
20 Web of Science
20 Crossref

Abstract PDF

Gastric cancer is a global health burden and has the highest incidence in East Asia. This disease is complex in nature because it arises from multiple interactions of genetic, local environmental, and host factors, resulting in biological heterogeneity. This genetic intricacy converges on molecular characteristics reflecting the pathophysiology, tumor biology, and clinical outcome. Therefore, understanding the molecular characteristics at a genomic level is pivotal to improving the clinical care of patients with gastric cancer. A recent landmark study, The Cancer Genome Atlas (TCGA) project, showed the molecular landscape of gastric cancer through a comprehensive molecular evaluation of 295 primary gastric cancers. The proposed molecular classification divided gastric cancer into four subtypes: Epstein-Barr virus–positive, microsatellite unstable, genomic stable, and chromosomal instability. This information will be taken into account in future clinical trials and will be translated into clinical therapeutic decisions. To fully realize the clinical benefit, many challenges must be overcome. Rapid growth of high-throughput biology and functional validation of molecular targets will further deepen our knowledge of molecular dimensions of this cancer, allowing for personalized precision medicine.

Citations

Citations to this article as recorded by

Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies
Marina Nishimuni, Laura Carolina Lopez Claro, Maria Ignez Freitas Melro Braghiroli
Surgical and Experimental Pathology.2024;[Epub] CrossRef
Research Progress of MSI Gastric Cancer Subtypes
成菊马
Advances in Clinical Medicine.2022; 12(07): 6719. CrossRef
OCT4-mediated transcription confers oncogenic advantage for a subset of gastric tumors with poor clinical outcome
Jaishree Pandian, Ponmathi Panneerpandian, Balaji T. Sekar, Karthikeyan Selvarasu, Kumaresan Ganesan
Functional & Integrative Genomics.2022; 22(6): 1345. CrossRef
Secondary Primary Cancer after Primary Gastric Cancer: Literature Review and Big Data Analysis Using the Health Insurance Review and Assessment Service (HIRA) Database of Republic of Korea
Jeong Ho Song, Yeonkyoung Lee, Jaesung Heo, Sang-Yong Son, Hoon Hur, Sang-Uk Han
Cancers.2022; 14(24): 6165. CrossRef
Microsatellite instability: a review of what the oncologist should know
Kai Li, Haiqing Luo, Lianfang Huang, Hui Luo, Xiao Zhu
Cancer Cell International.2020;[Epub] CrossRef
Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial
Chul Kyu Roh, Yoon Young Choi, Seohee Choi, Won Jun Seo, Minah Cho, Eunji Jang, Taeil Son, Hyoung-Il Kim, Hyeseon Kim, Woo Jin Hyung, Yong-Min Huh, Sung Hoon Noh, Jae-Ho Cheong
Yonsei Medical Journal.2019; 60(2): 132. CrossRef
Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon
Yoon Young Choi, Minah Cho, In Gyu Kwon, Taeil Son, Hyoung-Il Kim, Seung Ho Choi, Jae-Ho Cheong, Woo Jin Hyung
Yonsei Medical Journal.2019; 60(3): 235. CrossRef
Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer
Yujun Park, Jiwon Koh, Yoonjin Kwak, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
Cancer Immunology, Immunotherapy.2019; 68(11): 1779. CrossRef
Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer
Mengsha Tong, Chunyu Yu, Jinwen Shi, Wenwen Huang, Sai Ge, Mingwei Liu, Lei Song, Dongdong Zhan, Xia Xia, Wanlin Liu, Jinwen Feng, Wenhao Shi, Jiafu Ji, Jing Gao, Tieliu Shi, Weimin Zhu, Chen Ding, Yi Wang, Fuchu He, Lin Shen, Tingting Li, Jun Qin
iScience.2019; 22: 44. CrossRef
Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients
Jiwon Koh, Soo Kyung Nam, Youn Woo Lee, Jin Won Kim, Keun-Wook Lee, Chan-Young Ock, Do-Youn Oh, Sang-Hoon Ahn, Hyung-Ho Kim, Keon-Wook Kang, Woo Ho Kim, Ho-Young Lee, Hye Seung Lee
Biomolecules.2019; 9(12): 782. CrossRef
Targeted drug delivery of capecitabine to mice xenograft gastric cancer by PAMAM dendrimer nanocarrier
Sharareh Jafari, Fatemeh Nabavizadeh, Jalal Vahedian, Mehdi Shafie Ardestani, Hedayat Samandari, Ali Zare Mehrjerdi
african journal of gastroenterology and hepatology.2019; 2(1): 28. CrossRef
New therapeutic options opened by the molecular classification of gastric cancer
Mihaela Chivu-Economescu, Lilia Matei, Laura G Necula, Denisa L Dragu, Coralia Bleotu, Carmen C Diaconu
World Journal of Gastroenterology.2018; 24(18): 1942. CrossRef
Proposed Molecular and miRNA Classification of Gastric Cancer
Lara Alessandrini, Melissa Manchi, Valli De Re, Riccardo Dolcetti, Vincenzo Canzonieri
International Journal of Molecular Sciences.2018; 19(6): 1683. CrossRef
High serum MMP-14 predicts worse survival in gastric cancer
Aaro Kasurinen, Taina Tervahartiala, Alli Laitinen, Arto Kokkola, Timo Sorsa, Camilla Böckelman, Caj Haglund, Dajun Deng
PLOS ONE.2018; 13(12): e0208800. CrossRef
miR-30 functions as an oncomiR in gastric cancer cells through regulation of P53-mediated mitochondrial apoptotic pathway
Jianjun Wang, Yang Jiao, Lunmeng Cui, Lili Jiang
Bioscience, Biotechnology, and Biochemistry.2017; 81(1): 119. CrossRef
Clinicopathologic implication of meticulous pathologic examination of regional lymph nodes in gastric cancer patients
Jiwon Koh, Hee Eun Lee, Woo Ho Kim, Hye Seung Lee, Ju-Seog Lee
PLOS ONE.2017; 12(3): e0174814. CrossRef
Perioperative chemotherapy for resectable gastric cancer – what is the evidence?
Erling A Bringeland, Hans H Wasmuth, Jon E Grønbech
Scandinavian Journal of Gastroenterology.2017; 52(6-7): 647. CrossRef
Molecular classifications of gastric cancers: Novel insights and possible future applications
Silvio Ken Garattini, Debora Basile, Monica Cattaneo, Valentina Fanotto, Elena Ongaro, Marta Bonotto, Francesca V Negri, Rosa Berenato, Paola Ermacora, Giovanni Gerardo Cardellino, Mariella Giovannoni, Nicoletta Pella, Mario Scartozzi, Lorenzo Antonuzzo,
World Journal of Gastrointestinal Oncology.2017; 9(5): 194. CrossRef
GRAM domain-containing protein 1B (GRAMD1B), a novel component of the JAK/STAT signaling pathway, functions in gastric carcinogenesis
Puja Khanna, Pei Jou Chua, Belinda Shu Ee Wong, Changhong Yin, Aye Aye Thike, Wei Keat Wan, Puay Hoon Tan, Gyeong Hun Baeg
Oncotarget.2017; 8(70): 115370. CrossRef
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
Jiwon Koh, Chan-Young Ock, Jin Won Kim, Soo Kyung Nam, Yoonjin Kwak, Sumi Yun, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
Oncotarget.2017; 8(16): 26356. CrossRef

The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing: Michael H. Roh; J Pathol Transl Med. 2015;49(4):300-309. Published online June 16, 2015; DOI: https://doi.org/10.4132/jptm.2015.06.16

13,737 View
157 Download
33 Web of Science
31 Crossref

Abstract PDF

In this era of precision medicine, our understanding and knowledge of the molecular landscape associated with lung cancer pathogenesis continues to evolve. This information is being increasingly exploited to treat advanced stage lung cancer patients with tailored, targeted therapy. During the management of these patients, minimally invasive procedures to obtain samples for tissue diagnoses are desirable. Cytologic fine-needle aspirates are often utilized for this purpose and are important not only for rendering diagnoses to subtype patients’ lung cancers, but also for ascertaining molecular diagnostic information for treatment purposes. Thus, cytologic fine-needle aspirates must be utilized and triaged judiciously to achieve both objectives. In this review, strategies in utilizing fine-needle aspirates will be discussed in the context of our current understanding of the clinically actionable molecular aberrations underlying non-small cell lung cancer and the molecular assays applied to these samples in order to obtain treatment-relevant molecular diagnostic information.

Citations

Citations to this article as recorded by

The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non–small cell lung cancer
Sinchita Roy‐Chowdhuri, Haresh Mani, Adam H. Fox, Anne Tsao, Lynette M. Sholl, Farhood Farjah, Bruce E. Johnson, Raymond U. Osarogiagbon, M. Patricia Rivera, Gerard A. Silvestri, Robert A. Smith, Ignacio I. Wistuba
Cancer.2024;[Epub] CrossRef
Endobronchial ultrasound bronchoscopy Franseen fine needle biopsy tool versus standard fine needle aspiration needle: Impact on diagnosis and tissue adequacy
Matthew C. Aboudara, Timothy Saettele, Ossama Tawfik
Respiratory Medicine.2023; 208: 107131. CrossRef
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy
Erin Faber, Horiana Grosu, Sharjeel Sabir, Francis Anthony San Lucas, Bedia A Barkoh, Roland L Bassett, Rajyalakshmi Luthra, John Stewart, Sinchita Roy-Chowdhuri
Journal of Clinical Pathology.2022; 75(9): 612. CrossRef
Biomarker testing of cytology specimens in personalized medicine for lung cancer patients
Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(6): 326. CrossRef
Formalin fixation for optimal concordance of programmed death‐ligand 1 immunostaining between cytologic and histologic specimens from patients with non–small cell lung cancer
Bregje M. Koomen, Jose van der Starre‐Gaal, Judith M. Vonk, Jan H. von der Thüsen, Jacqueline J. C. van der Meij, Kim Monkhorst, Stefan M. Willems, Wim Timens, Nils A. ’t Hart
Cancer Cytopathology.2021; 129(4): 304. CrossRef
Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guidelines from the College of American Pathologists (CAP)
Sinchita Roy-Chowdhuri
Journal of Molecular Pathology.2021; 2(1): 23. CrossRef
A decade of change: Trends in the practice of cytopathology at a tertiary care cancer centre
Peyman Dinarvand, Chinhua Liu, Sinchita Roy‐Chowdhuri
Cytopathology.2021; 32(5): 604. CrossRef
False‐negative programmed death‐ligand 1 immunostaining in ethanol‐fixed endobronchial ultrasound‐guided transbronchial needle aspiration specimens of non‐small‐cell lung cancer patients
Bregje M Koomen, Willem Vreuls, Mirthe de Boer, Emma J de Ruiter, Juergen Hoelters, Aryan Vink, Stefan M Willems
Histopathology.2021; 79(4): 480. CrossRef
Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry
Teodora Radonic, S. Duin, W. Vos, P. Kortman, Aeilko H. Zwinderman, Erik Thunnissen
Virchows Archiv.2021; 478(2): 293. CrossRef
Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients
Wei Wu, Ziyang Cao, Wei Zhang, Liping Zhang, Likun Hou, Chunyan Wu
Diagnostic Pathology.2020;[Epub] CrossRef
Tumor cell representation by an improvised technique of fine-needle aspiration specimen acquisition and cell block preparation: Our experience in lung cancer cases in a peripheral center of eastern India
AnupKr Boler, Shreosee Roy, Arghya Bandyopadhyay, Abhishek Bandyopadhyay, MrinalKanti Ghosh
Journal of Cytology.2020; 37(2): 87. CrossRef
A new guideline from the College of American Pathologists to improve the adequacy of thoracic small specimens for ancillary studies
Sinchita Roy‐Chowdhuri
Cancer Cytopathology.2020; 128(10): 690. CrossRef
The utilization of cytologic and small biopsy samples for ancillary molecular testing
Michael H. Roh
Modern Pathology.2019; 32: 77. CrossRef
Diff-Quik Cytology Smears from Endobronchial Ultrasound Transbronchial Needle Aspiration Lymph Node Specimens as a Source of DNA for Next-Generation Sequencing Instead of Cell Blocks
David Fielding, Andrew J. Dalley, Farzad Bashirzadeh, Mahendra Singh, Lakshmy Nandakumar, Amy E. McCart Reed, Debra Black, Stephen Kazakoff, John V. Pearson, Katia Nones, Nicola Waddell, Sunil R. Lakhani, Peter T. Simpson
Respiration.2019; 97(6): 525. CrossRef
Molecular testing on endobronchial ultrasound (EBUS) fine needle aspirates (FNA): Impact of triage
Simon Sung, John P. Crapanzano, David DiBardino, David Swinarski, William A. Bulman, Anjali Saqi
Diagnostic Cytopathology.2018; 46(2): 122. CrossRef
Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling
Sinchita Roy-Chowdhuri, Meenakshi Mehrotra, Ana Maria Bolivar, Rashmi Kanagal-Shamanna, Bedia A. Barkoh, Brette Hannigan, Stephanie Zalles, Wenrui Ye, Dzifa Duose, Russell Broaddus, Gregg Staerkel, Ignacio Wistuba, L. Jeffrey Medeiros, Rajyalakshmi Luthra
Modern Pathology.2018; 31(7): 1036. CrossRef
Fluorescence in situ hybridization analysis on cytologic smears: An accurate and efficient method in the diagnosis of melanotic Xp11 translocation renal cancer
Alia Gupta, Mark Micale, Kurt D. Bernacki
Diagnostic Cytopathology.2018; 46(9): 786. CrossRef
Comprehensive Validation of Cytology Specimens for Next-Generation Sequencing and Clinical Practice Experience
Agnes Balla, Ken J. Hampel, Mukesh K. Sharma, Catherine E. Cottrell, Nikoletta Sidiropoulos
The Journal of Molecular Diagnostics.2018; 20(6): 812. CrossRef
Advances in Molecular Testing Techniques in Cytologic Specimens
Sinchita Roy-Chowdhuri
Surgical Pathology Clinics.2018; 11(3): 669. CrossRef
Next-generation molecular diagnosis: single-cell sequencing from bench to bedside
Wanjun Zhu, Xiao-Yan Zhang, Sadie L. Marjani, Jialing Zhang, Wengeng Zhang, Shixiu Wu, Xinghua Pan
Cellular and Molecular Life Sciences.2017; 74(5): 869. CrossRef
Big data from small samples: Informatics of next‐generation sequencing in cytopathology
Sinchita Roy‐Chowdhuri, Somak Roy, Sara E. Monaco, Mark J. Routbort, Liron Pantanowitz
Cancer Cytopathology.2017; 125(4): 236. CrossRef
Next‐generation sequencing of liquid‐based cytology non–small cell lung cancer samples
Jordan P. Reynolds, Yaolin Zhou, Maureen A. Jakubowski, Zhen Wang, Jennifer A. Brainard, Roger D. Klein, Carol F. Farver, Francisco A. Almeida, Yu‐Wei Cheng
Cancer Cytopathology.2017; 125(3): 178. CrossRef
Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies
Sinchita Roy-Chowdhuri, Hui Chen, Rajesh R Singh, Savitri Krishnamurthy, Keyur P Patel, Mark J Routbort, Jawad Manekia, Bedia A Barkoh, Hui Yao, Sharjeel Sabir, Russell R Broaddus, L Jeffrey Medeiros, Gregg Staerkel, John Stewart, Rajyalakshmi Luthra
Modern Pathology.2017; 30(4): 499. CrossRef
Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization–based assay: Cytological smears versus cell blocks
Federica Zito Marino, Giulio Rossi, Matteo Brunelli, Maria Gabriella Malzone, Giuseppina Liguori, Giuseppe Bogina, Alessandro Morabito, Gaetano Rocco, Renato Franco, Gerardo Botti
Cancer Cytopathology.2017; 125(5): 303. CrossRef
Next‐generation sequencing of cytologic preparations: An analysis of quality metrics
David H. Hwang, Elizabeth P. Garcia, Matthew D. Ducar, Edmund S. Cibas, Lynette M. Sholl
Cancer Cytopathology.2017; 125(10): 786. CrossRef
Recent advances in the pathology and molecular genetics of lung cancer: A practical review for cytopathologists
Erika F. Rodriguez, Sara E. Monaco
Journal of the American Society of Cytopathology.2016; 5(5): 252. CrossRef
Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology
Lester J. Layfield, Sinchita Roy‐Chowdhuri, Zubair Baloch, Hormoz Ehya, Kim Geisinger, Susan J. Hsiao, Oscar Lin, Neal I. Lindeman, Michael Roh, Fernando Schmitt, Nikoletta Sidiropoulos, Paul A. VanderLaan
Diagnostic Cytopathology.2016; 44(12): 1000. CrossRef
Inflammatory myofibroblastic tumour
Michael McDermott
Seminars in Diagnostic Pathology.2016; 33(6): 358. CrossRef
Preanalytic Variables in Cytology: Lessons Learned From Next-Generation Sequencing—The MD Anderson Experience
Sinchita Roy-Chowdhuri, John Stewart
Archives of Pathology & Laboratory Medicine.2016; 140(11): 1191. CrossRef
Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society
Sinchita Roy-Chowdhuri, Dara L. Aisner, Timothy Craig Allen, Mary Beth Beasley, Alain Borczuk, Philip T. Cagle, Vera Capelozzi, Sanja Dacic, Gilda da Cunha Santos, Lida P. Hariri, Keith M. Kerr, Sylvie Lantuejoul, Mari Mino-Kenudson, Andre Moreira, Kirtee
Archives of Pathology & Laboratory Medicine.2016; 140(11): 1267. CrossRef
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma
Mi-Sook Lee, Ryong Nam Kim, Hoseok I, Doo-Yi Oh, Ji-Young Song, Ka-Won Noh, Yu-Jin Kim, Jung Wook Yang, Maruja E. Lira, Chang Hun Lee, Min Ki Lee, Yeoung Dae Kim, Mao Mao, Joungho Han, Jhingook Kim, Yoon-La Choi
Oncotarget.2016; 7(24): 36101. CrossRef

Molecular Imaging in the Era of Personalized Medicine: Kyung-Ho Jung, Kyung-Han Lee; J Pathol Transl Med. 2015;49(1):5-12. Published online January 15, 2015; DOI: https://doi.org/10.4132/jptm.2014.10.24

12,086 View
201 Download
30 Web of Science
25 Crossref

Abstract PDF

Clinical imaging creates visual representations of the body interior for disease assessment. The role of clinical imaging significantly overlaps with that of pathology, and diagnostic workflows largely depend on both fields. The field of clinical imaging is presently undergoing a radical change through the emergence of a new field called molecular imaging. This new technology, which lies at the intersection between imaging and molecular biology, enables noninvasive visualization of biochemical processes at the molecular level within living bodies. Molecular imaging differs from traditional anatomical imaging in that biomarkers known as imaging probes are used to visualize target molecules-of-interest. This ability opens up exciting new possibilities for applications in oncologic, neurological and cardiovascular diseases. Molecular imaging is expected to make major contributions to personalized medicine by allowing earlier diagnosis and predicting treatment response. The technique is also making a huge impact on pharmaceutical development by optimizing preclinical and clinical tests for new drug candidates. This review will describe the basic principles of molecular imaging and will briefly touch on three examples (from an immense list of new techniques) that may contribute to personalized medicine: receptor imaging, angiogenesis imaging, and apoptosis imaging.

Citations

Citations to this article as recorded by

Supramolecular fluorescence biosensing based on macrocycles
Jia-Hong Tian, Haiqi Xu, Xin-Yue Hu, Dong-Sheng Guo
Supramolecular Materials.2024; 3: 100063. CrossRef
A non-invasive osteopontin-targeted phase changeable fluorescent nanoprobe for molecular imaging of myocardial fibrosis
Xueli Zhao, Yuze Qin, Bo Wang, Jiao Liu, Yueyue Wang, Kun Chen, Jia Zhao, Lanlan Zhang, Yuanming Wu, Liwen Liu
Nanoscale Advances.2024; 6(14): 3590. CrossRef
The Role of Molecular Imaging in Personalized Medicine
Suliman Salih, Aisyah Elliyanti, Ajnas Alkatheeri, Fatima AlYafei, Bashayer Almarri, Hasina Khan
Journal of Personalized Medicine.2023; 13(2): 369. CrossRef
Development of a multifunctional platform for near-infrared imaging and targeted radionuclide therapy for tumors
Huihui He, Ke Li, Hang Li, Shiliang Zhu, Shuai Qin, Yong Mao, Jianguo Lin, Ling Qiu, Chunjing Yu
European Journal of Pharmaceutics and Biopharmaceutics.2023; 185: 107. CrossRef
Quantum Biotechnology
Nicolas P. Mauranyapin, Alex Terrasson, Warwick P. Bowen
Advanced Quantum Technologies.2022;[Epub] CrossRef
Preparation Fe3O4@chitosan-graphene quantum dots nanocomposites for fluorescence and magnetic resonance imaging
Kai Wang, Xiaoguang Xu, Yan Li, Mayifei Rong, Lifeng Wang, Liying Lu, Jian Wang, Fengwen Zhao, Bowen Sun, Yong Jiang
Chemical Physics Letters.2021; 783: 139060. CrossRef
Network Medicine: A Clinical Approach for Precision Medicine and Personalized Therapy in Coronary Heart Disease
Teresa Infante, Luca Del Viscovo, Maria Luisa De Rimini, Sergio Padula, Pio Caso, Claudio Napoli
Journal of Atherosclerosis and Thrombosis.2020; 27(4): 279. CrossRef
Nanodrug Delivery Systems for the Treatment of Ovarian Cancer
Jonathan M. Pantshwa, Pierre P. D. Kondiah, Yahya E. Choonara, Thashree Marimuthu, Viness Pillay
Cancers.2020; 12(1): 213. CrossRef
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer
V. M. Baart, R. D. Houvast, L. F. de Geus-Oei, P. H. A. Quax, P. J. K. Kuppen, A. L. Vahrmeijer, C. F. M. Sier
EJNMMI Research.2020;[Epub] CrossRef
In vivo SPECT imaging of an 131I-labeled PM 2.5 mimic substitute
Dong-Hui Pan, Jie Sheng, Xin-Yu Wang, Qian-Huan Huang, Jun-Jie Yan, Li-Zhen Wang, Run-Ling Yang, Dong-Jian Shi, Yu-Ping Xu, Ming-Qing Chen
Nuclear Science and Techniques.2020;[Epub] CrossRef
Optofluidics in bio-imaging applications
Sihui Chen, Rui Hao, Yi Zhang, Hui Yang
Photonics Research.2019; 7(5): 532. CrossRef
Nitrogen-vacancy centers in diamond for nanoscale magnetic resonance imaging applications
Alberto Boretti, Lorenzo Rosa, Jonathan Blackledge, Stefania Castelletto
Beilstein Journal of Nanotechnology.2019; 10: 2128. CrossRef
Online molecular image repository and analysis system: A multicenter collaborative open-source infrastructure for molecular imaging research and application
Mahabubur Rahman, Hiroshi Watabe
Computers in Biology and Medicine.2018; 96: 233. CrossRef
Nε-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure–Activity Relationships, and Pharmacokinetic Profiling
Robert Wodtke, Christoph Hauser, Gloria Ruiz-Gómez, Elisabeth Jäckel, David Bauer, Martin Lohse, Alan Wong, Johanna Pufe, Friedrich-Alexander Ludwig, Steffen Fischer, Sandra Hauser, Dieter Greif, M. Teresa Pisabarro, Jens Pietzsch, Markus Pietsch, Reik Lö
Journal of Medicinal Chemistry.2018; 61(10): 4528. CrossRef
Genomic Interventions in Medicine
Oluwadurotimi S Aworunse, Oluwatomiwa Adeniji, Olusola L Oyesola, Itunuoluwa Isewon, Jelili Oyelade, Olawole O Obembe
Bioinformatics and Biology Insights.2018;[Epub] CrossRef
Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI
Ryan L. Brunsing, Natalie M. Schenker-Ahmed, Nathan S. White, J. Kellogg Parsons, Christopher Kane, Joshua Kuperman, Hauke Bartsch, Andrew Karim Kader, Rebecca Rakow-Penner, Tyler M. Seibert, Daniel Margolis, Steven S. Raman, Carrie R. McDonald, Nikdokht
Journal of Magnetic Resonance Imaging.2017; 45(2): 323. CrossRef
Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium
Orazio Schillaci, Nicoletta Urbano
European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(4): 563. CrossRef
Nano-Magnetic Resonance Imaging (Nano-MRI) Gives Personalized Medicine a New Perspective
Lorenzo Rosa, Jonathan Blackledge, Albert Boretti
Biomedicines.2017; 5(1): 7. CrossRef
Optical nanoprobes for biomedical applications: shining a light on upconverting and near-infrared emitting nanoparticles for imaging, thermal sensing, and photodynamic therapy
E. Hemmer, P. Acosta-Mora, J. Méndez-Ramos, S. Fischer
Journal of Materials Chemistry B.2017; 5(23): 4365. CrossRef
Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma
Senthilkumar Kalimuthu, Ju Hye Jeong, Ji Min Oh, Byeong-Cheol Ahn
International Journal of Molecular Sciences.2017; 18(8): 1639. CrossRef
Chemistry and engineering of cyclodextrins for molecular imaging
Wing-Fu Lai, Andrey L. Rogach, Wing-Tak Wong
Chemical Society Reviews.2017; 46(20): 6379. CrossRef
Prototypes of Lanthanide(III) Agents Responsive to Enzymatic Activities in Three Complementary Imaging Modalities: Visible/Near-Infrared Luminescence, PARACEST-, and T1-MRI
Jiefang He, Célia S. Bonnet, Svetlana V. Eliseeva, Sara Lacerda, Thomas Chauvin, Pascal Retailleau, Frederic Szeremeta, Bernard Badet, Stéphane Petoud, Éva Tóth, Philippe Durand
Journal of the American Chemical Society.2016; 138(9): 2913. CrossRef
Nanoparticles in practice for molecular-imaging applications: An overview
Parasuraman Padmanabhan, Ajay Kumar, Sundramurthy Kumar, Ravi Kumar Chaudhary, Balázs Gulyás
Acta Biomaterialia.2016; 41: 1. CrossRef
A new neuroinformatics approach to personalized medicine in neurology: The Virtual Brain
Maria I. Falcon, Viktor Jirsa, Ana Solodkin
Current Opinion in Neurology.2016; 29(4): 429. CrossRef
Targeted multimodal nano-reporters for pre-procedural MRI and intra-operative image-guidance
Joonseok Lee, Andrew C. Gordon, Hacksung Kim, Wooram Park, Soojeong Cho, Byeongdu Lee, Andrew C. Larson, Elena A. Rozhkova, Dong-Hyun Kim
Biomaterials.2016; 109: 69. CrossRef

Case Report

Gastric Adenocarcinoma of Fundic Gland Type: Report of Three Cases: Eun Su Park, Young Eun Kim, Cheol Keun Park, Takashi Yao, Ryoji Kushima, Kyoung-Mee Kim; Korean J Pathol. 2012;46(3):287-291. Published online June 22, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.3.287

9,593 View
103 Download
24 Crossref

Abstract PDF

Recently, fundic gland type gastric adenocarcinoma (GA-FG) has been reported as a new entity. This report describes GA-FG among Koreans for the first time. From March 2008 to July 2010 we identified only three cases of GA-FG out of over 6,000 GAs resected by endoscopy or surgery. Cell differentiation by mucin proteins, pepsinogen-I, and H+/K+-ATPase was evaluated. All three cases were male patients and diagnosed as early stage GA. Histologically, GA-FGs were well-differentiated adenocarcinoma with pale gray-blue, basophilic columnar or cuboidal cells and mildly enlarged nuclei, resembling chief cells. All three cases were positive for pepsinogen-I and were classified as gastric mucin phenotype. Among three histologic subtypes of GA-FG, since tumors were mainly composed of chief cells, our three cases were classified as chief cell predominant type. In conclusion, GA-FG is very rare among Koreans and pepsinogen-I and MUC6 expression are typical immunohistochemical findings in GA-FG suggesting differentiation toward fundic glands.

Citations

Citations to this article as recorded by

Oxyntic Gland Neoplasms - From Adenoma to Advanced Gastric Cancer: A Review of 29 Cases
Gi Hwan Kim, Jun Su Lee, Jeong Hoon Lee, Young Soo Park
Journal of Gastric Cancer.2024; 24(4): 378. CrossRef
Transcriptome analysis reveals the essential role of NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) in gastric adenocarcinoma of fundic-gland type
Kazushi Fukagawa, Yu Takahashi, Nobutake Yamamichi, Natsuko Kageyama-Yahara, Yoshiki Sakaguchi, Miho Obata, Rina Cho, Nobuyuki Sakuma, Sayaka Nagao, Yuko Miura, Naoki Tamura, Daisuke Ohki, Hiroya Mizutani, Seiichi Yakabi, Chihiro Minatsuki, Keiko Niimi, Y
Gastric Cancer.2023; 26(1): 44. CrossRef
Clinicopathological Features and the Prevalence of Oxyntic Gland Neoplasm: A Single-center Retrospective Study
Hikari Asahara, Toshitatsu Takao, Yumiko Asahara, Masakyo Asahara, Douglas Motomura, Hiroya Sakaguchi, Tetsuya Yoshizaki, Nobuaki Ikezawa, Madoka Takao, Yoshinori Morita, Takashi Toyonaga, Masato Komatsu, Ryoji Kushima, Yuzo Kodama
Internal Medicine.2023; 62(19): 2763. CrossRef
Clinicopathological features of gastric adenocarcinoma of fundic gland type
Bao-Zhen Guo, Zhen-Zhen Liu, Gao-Fei Shen, Fei Zhu, Hui-Fen Lian, Xin Li, Jun-Yi Zheng, Jin-Peng Li, Shui-Miao Deng, Rui Huang
World Chinese Journal of Digestology.2023; 31(6): 244. CrossRef
Endoscopic Resection for Gastric Adenocarcinoma of the Fundic Gland Type: A Case Series
Hwa Jin Lee, Gwang Ha Kim, Dong Chan Joo, Moon Won Lee, Bong Eun Lee, Kyungbin Kim
The Korean Journal of Gastroenterology.2023; 81(6): 259. CrossRef
Gastric adenocarcinoma of the fundic gland type: A review of the literature
Zhiyong Zhai, Wei Hu, Zhaoyu Huang, Zemin Chen, Sicun Lu, Wei Gong
JGH Open.2023; 7(12): 812. CrossRef
Clinicopathological features of early stage gastric adenocarcinoma of fundic gland type
Huan Zhang, Shuyan Wang, Yongping Zhang, Fusang Ye, Chunnian Wang
Medicine.2022; 101(2): e28469. CrossRef
Gastric Adenocarcinoma of Fundic Gland Type Treated by Endoscopic Submucosal Dissection
Yong Bo Park, Gwang Ha Kim, Kyungbin Kim, Tae Kyoung Ha, Guk Bin Park, Young Min Kwak
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(1): 82. CrossRef
Gastric epithelial neoplasm of fundic-gland mucosa lineage: proposal for a new classification in association with gastric adenocarcinoma of fundic-gland type
Hiroya Ueyama, Takashi Yao, Yoichi Akazawa, Takuo Hayashi, Koichi Kurahara, Yumi Oshiro, Masayoshi Yamada, Ichiro Oda, Shin Fujioka, Chiaki Kusumoto, Masayoshi Fukuda, Kunihisa Uchita, Tomohiro Kadota, Yasuhiro Oono, Kazuhisa Okamoto, Kazunari Murakami, Y
Journal of Gastroenterology.2021; 56(9): 814. CrossRef
Endoscopic resection is a suitable initial treatment strategy for oxyntic gland adenoma or gastric adenocarcinoma of the fundic gland type
Masaya Iwamuro, Chiaki Kusumoto, Masahiro Nakagawa, Sayo Kobayashi, Masao Yoshioka, Tomoki Inaba, Tatsuya Toyokawa, Shinichiro Hori, Shouichi Tanaka, Kazuhiro Matsueda, Takehiro Tanaka, Hiroyuki Okada
Scientific Reports.2021;[Epub] CrossRef
A series of five patients with oxyntic gland adenoma: Deciphering the clinical and histological features of these rare gastric polyps
Jerry C. Nagaputra, Tracy Jie Zhen Loh, Sangeeta Mantoo, Rafay Azhar, Vikneswaran Namasivayam, Wei Qiang Leow
Human Pathology Reports.2021; 26: 300566. CrossRef
Gastric adenocarcinoma of the fundic gland: A review of clinicopathological characteristics, treatment and prognosis
Xiang-yu Meng, Guang Yang, Cheng-ji Dong, Ru-yi Zheng
Rare Tumors.2021;[Epub] CrossRef
Gastric adenocarcinoma of the fundic gland type: clinicopathological features of eight patients treated with endoscopic submucosal dissection
Chengfang Li, Xinglong Wu, Shuang Yang, Xiaorong Yang, Jin Yao, Hong Zheng
Diagnostic Pathology.2020;[Epub] CrossRef
Multiple gastric adenocarcinoma of fundic gland type: A case report
Ou Chen, Ze-Yong Shao, Xiong Qiu, Guang-Ping Zhang
World Journal of Clinical Cases.2019; 7(18): 2871. CrossRef
Gastric Adenocarcinoma of the Fundic Gland Type
Mark A Benedict, Gregory Y Lauwers, Dhanpat Jain
American Journal of Clinical Pathology.2018; 149(6): 461. CrossRef
Oxyntic Gland Adenoma Treated by Endoscopic Mucosal Resection
In Ji Song, Jin Woo Joo, Jun Chul Park, Sung Kwan Shin, Yong Chan Lee, Sang Kil Lee
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(2): 94. CrossRef
Chief cell‐predominant gastric polyps: a series of 12 cases with literature review
Karen Chan, Ian S Brown, Trevor Kyle, Gregory Y Lauwers, Marian Priyanthi Kumarasinghe
Histopathology.2016; 68(6): 825. CrossRef
Twelve-year natural history of a gastric adenocarcinoma of fundic gland type
Yoshinori Sato, Takashi Fujino, Akira Kasagawa, Ryo Morita, Shun-ichiro Ozawa, Yasumasa Matsuo, Tadateru Maehata, Hiroshi Yasuda, Masayuki Takagi, Fumio Itoh
Clinical Journal of Gastroenterology.2016; 9(6): 345. CrossRef
Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings
Takashi Chiba, Katsuaki Kato, Takayuki Masuda, Shuichi Ohara, Noriyuki Iwama, Takenobu Shimada, Daisuke Shibuya
Digestive Endoscopy.2016; 28(7): 722. CrossRef
Gastric Adenocarcinoma of the Fundic Gland Type Treated by Endoscopic Mucosal Resection: A Case Report and Review of the Literature
Eleanor Lewin, Philip Daroca, Sanjay Sikka, Tong Wu, Yukihiro Nakanishi
Case Reports in Pathology.2016; 2016: 1. CrossRef
Gastric adenocarcinoma of the fundic gland (chief cell-predominant type): A review of endoscopic and clinicopathological features
Masaki Miyazawa, Mitsuru Matsuda, Masaaki Yano, Yasumasa Hara, Fumitaka Arihara, Yosuke Horita, Koichiro Matsuda, Akito Sakai, Yatsugi Noda
World Journal of Gastroenterology.2016; 22(48): 10523. CrossRef
Oxyntic gland adenoma endoscopically mimicking a gastric neuroendocrine tumor: A case report
Tae-In Lee
World Journal of Gastroenterology.2015; 21(16): 5099. CrossRef
Oxyntic gland polyp/adenoma
Rajkumar Vajpeyi, Jyoti Dekate
Diagnostic Histopathology.2014; 20(11): 446. CrossRef
Gastric adenocarcinoma of fundic gland type with unusual behavior
Tetsuya Ueo, Hirotoshi Yonemasu, Tetsuya Ishida
Digestive Endoscopy.2014; 26(2): 293. CrossRef

First
Prev
Page of 2
Next
Last

Search